Page 8 - Remunity Pump News Today

Emerald Mutual Fund Advisers Trust trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 17.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,903 shares of the biotechnology company’s stock after selling 11,935 shares during the period. Emerald Mutual […]

Daiwa Securities Group Inc. raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 1,530.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,983 shares of the biotechnology company’s stock after buying an additional 2,800 shares […]

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) EVP Paul A. Mahon sold 2,500 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $243.87, for a total value of $609,675.00. Following the sale, the executive vice president now directly owns 36,599 shares […]

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) EVP Paul A. Mahon sold 2,500 shares of United Therapeutics stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $243.87, for a total value of $609,675.00. Following the completion of the transaction, the executive vice president now directly owns […]

Pacer Advisors Inc. boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 1,567.0% during the first quarter, Holdings Channel.com reports. The firm owned 172,101 shares of the biotechnology company’s stock after purchasing an additional 161,777 shares during the quarter. Pacer Advisors Inc.’s holdings in United Therapeutics were worth $38,544,000 as […]

United Therapeutics (NASDAQ:UTHR – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday. A number of other equities analysts have also recently issued reports on UTHR. UBS Group dropped their target price on United Therapeutics from $330.00 to $310.00 […]

Shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) have been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price […]

United Therapeutics Co. (NASDAQ:UTHR – Free Report) – Zacks Research lifted their FY2023 earnings per share estimates for United Therapeutics in a note issued to investors on Monday, July 3rd. Zacks Research analyst K. Shah now anticipates that the biotechnology company will post earnings per share of $17.62 for the year, up from their prior […]

Shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month price […]

Shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) have earned an average rating of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 1-year price […]